Abstract Details

Title The Hidden Disease Burden and Treatment Experience of Patients with Essential Tremor: A Retrospective US Claims Analysis

Topic Movement Disorders

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 255

Objective To describe the attributes of patients with essential tremor (ET), associated comorbidities, and ET treatments using a US 2019 claims database.

Background ET is estimated to affect ~7 million people in the US; however, many patients remain undiagnosed, misdiagnosed and untreated, highlighting the need to understand its true impact on affected patients.

Design/Methods This retrospective observational study examined medical and prescription claims from the Compile database (https://www.compile.com/data), capturing data for ~300 million patients from 2015–2019. Presence of ET, comorbidities, and ET treatments used were assessed for 2019, and analysis of longitudinal patterns before and after ET diagnosis incorporated data from 2015-2019. ET was identified by the presence of a diagnostic ICD-10 code (G25.0) plus at least 2 relevant ET prescriptions, or 2 ICD-10 codes (G25.0 and R25.1 for unspecified tremor) at least 90 days apart. Descriptive statistics summarized patient demographics, comorbidities, and treatment use.

Results A total of 128,263 patients had an ET diagnosis in 2019. About 75% of patients were ≥65 years, 57% were female, and 96% had at least 1 comorbidity. Comorbidities were common and included hypertension (73%), hyperlipidemia (68%), depression (44%), diabetes (31%), and anxiety (29%). About 64% of patients received at least 1 pharmacological treatment; only 3% opted for a procedural intervention. Propranolol (37%) and primidone (32%) were the most commonly prescribed pharmacologic therapies, with some patients prescribed more than 1 treatment. Within 2 years of treatment, medication discontinuation was 40% for propranolol and 47% for primidone.

Conclusions These findings highlight the hidden impact of ET. The prevalence of ET increases with age with 75% of patients over the age of 65. Almost all patients experience multiple comorbidities requiring various pharmacological therapies, adding to the complexity of patient care in ET. Together with high discontinuation rates for the 2 first-line treatments, our findings signify the urgent unmet need in ET.

Authors/Disclosures
Bernard M. Ravina, MD, MSCE (Voyager Therapeutics, Inc.) PRESENTER	Dr. Ravina has received personal compensation for serving as an employee of Praxis Precision Medicines. Dr. Ravina has stock in Praxis.
	No disclosure on file
Kelly E. Lyons, PhD (University of Kansas Medical Center)	Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Lyons has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Parkinson's Foundation. Dr. Lyons has a non-compensated relationship as a President with International Essential Tremor Foundation that is relevant to AAN interests or activities.
Gabriel M. Belfort, MD (BlueRock Therapeutics)	Dr. Belfort has received personal compensation for serving as an employee of Praxis Precision Medicines. Dr. Belfort has received stock or an ownership interest from Praxis Precision Medicines. Dr. Belfort has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��